SB 1039 (see companion bill HB 1324) – Maryland

Status: Inactive / Dead
Year Introduced: 2019
Link: http://mgaleg.maryland.gov/webmga/frmMain.aspx?id=sb1039&stab=01&pid=billpage&tab=subject3&ys=2019RS

Requiring the Maryland Medical Assistance Program to establish reimbursement levels, rather than maximum reimbursement levels, for certain drug products; requiring that certain minimum reimbursement levels be at least equal to the National Average Drug Acquisition Cost of the generic product plus a certain fee-for-service professional dispensing fee; providing that certain provisions of the Act apply to managed care organizations that use pharmacy benefits managers to manage prescription drug coverage; etc.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found